SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Mortensen Leif Spange)
 

Sökning: WFRF:(Mortensen Leif Spange) > (2015) > Radiofrequency cath...

Radiofrequency catheter ablation maintains its efficacy better than antiarrhythmic medication in patients with paroxysmal atrial fibrillation: On-treatment analysis of the randomized controlled MANTRA-PAF trial

Pekka Raatikainen, M. J. (författare)
Central Finland Health Care Dist, Finland; University of Eastern Finland, Finland,Kuopio University Hospital, Finland
Hakalahti, Antti (författare)
University of Oulu, Finland
Uusimaa, Paavo (författare)
University of Oulu, Finland
visa fler...
Cosedis Nielsen, Jens (författare)
Aarhus University Hospital, Denmark
Johannessen, Arne (författare)
Gentofte University Hospital, Denmark
Hindricks, Gerhard (författare)
Leipzig University Hospital, Germany
Walfridsson, Håkan (författare)
Linköpings universitet,Avdelningen för kardiovaskulär medicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken US
Pehrson, Steen (författare)
Rigshosp, Denmark
Englund, Anders (författare)
University Hospital, Sweden
Hartikainen, Juha (författare)
Kuopio University Hospital, Finland
Kongstad Rasmussen, Ole (författare)
Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,University of Lund Hospital, Sweden
Spange Mortensen, Leif (författare)
UNI C, Denmark
Steen Hansen, Peter (författare)
Aarhus University Hospital, Denmark
visa färre...
 (creator_code:org_t)
ELSEVIER IRELAND LTD, 2015
2015
Engelska.
Ingår i: International Journal of Cardiology. - : ELSEVIER IRELAND LTD. - 0167-5273 .- 1874-1754. ; 198, s. 108-114
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) is a randomized trial comparing radiofrequency catheter ablation (RFA) to antiarrhythmic drugs (AADs) as first-line treatment of paroxysmal atrial fibrillation (PAF). In order to eliminate the clouding effect of crossover we performed an on-treatment analysis of the data. Methods and results: Patients (n = 294) were divided into three groups: those receiving only the assigned therapy (RFA and AAD groups) and those receiving both therapies (crossover group). The primary end points were AF burden in 7-day Holter recordings at 3, 6, 12, 18, and 24 months and cumulative AF burden in all recordings. At 24 months, AF burden was significantly lower in the RFA (n = 110) than in the AAD (n = 92) and the crossover (n = 84) groups (90th percentile 1% vs. 10% vs. 16%, P = 0.007), and more patients were free from any AF (89% vs. 73% vs. 74%, P = 0.006). In the RFA, AAD and the crossover groups 63%, 59% and 21% (P less than 0.001) of the patients had no AF episodes in any Holter recording, respectively. Quality of life improved significantly in all groups. There were no differences in serious adverse events between the RFA, AAD and crossover groups (19% vs. 8% vs. 23%) (P = 0.10). Conclusions: In the treatment of antiarrhythmic therapy naive patients with PAF long-term efficacy of RFA was superior to AAD therapy. Thus, it is reasonable to offer RFA as first-line treatment for highly symptomatic patients who accept the risks of the procedure and are aware of frequent need for reablation(s). (C) 2015 Elsevier Ireland Ltd. All rights reserved.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Nyckelord

Atrial fibrillation; Catheter ablation; Antiarrhythmic drug; On-treatment analysis; Long-term efficacy

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy